BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Contrave: Additional Phase III data

Data from 182 patients in the ambulatory blood pressure monitoring (ABPM) sub-study of the double-blind, placebo-controlled, U.S. Phase III COR-II (NB-303) trial in 1,496 patients showed that patients treated with Contrave maintained normal 24-hour circadian patterns over 52 weeks of treatment. Additionally, Contrave-treated patients in the sub-study had significantly greater weight loss vs. placebo at week 52 (7.5% vs. 2.5%, p<0001). Contrave also significantly reduced waist circumference (7.5 vs. 2.3 cm, p<0.001)...

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >